S1PR2 and ulcerative colitis: In fact, two S1PR2 inhibitors, Etrasimod and Ozanimod have demonstrated potential as treatment options for individuals with ulcerative colitis, further highlighting the complexity of S1PR2 signaling in intestinal inflammation (63, 64).